J 2021

Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology

ZEYMERT, U., P. LUDMAN, N. DANCHIN, Petr KALA, C. LAROCHE et. al.

Základní údaje

Originální název

Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology

Autoři

ZEYMERT, U. (garant), P. LUDMAN, N. DANCHIN, Petr KALA (203 Česká republika, domácí), C. LAROCHE, M. SADEGHI, R. CAPORALE, S. M. SHAHEEN, J. LEGUTKO, Z. IAKOBSISHVILI, K. F. ALHABIB, Z. MOTOVSKA, M. STUDENCAN, J. MIMOSO, D. BECKER, D. ALEXOPOULOS, Z. KERESESELIDZE, S. STOJKOVIC, P. ZELVEIAN, A. GODA, E. MIRRAKHIMOV, G. BAJRAKTARI, H. AL-FARHAN, P. SERPYTIS, B. RAUNGAARD, T. MARANDI, A. M. MOORE, M. QUINN, P. P. KARJALAINEN, G. TATU-CHITOLU, C. P. GALE, A. P. MAGGIONI a F. WEIDINGER

Vydání

European heart journal, Oxford, Oxford University Press, 2021, 0195-668X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 35.855

Kód RIV

RIV/00216224:14110/21:00124152

Organizační jednotka

Lékařská fakulta

UT WoS

000738992000010

Klíčová slova anglicky

ST-elevation myocardial infarction; Primary percutaneous coronary intervention; Observational studies; Reperfusion therapy

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 17. 5. 2022 13:11, Mgr. Tereza Miškechová

Anotace

V originále

Aims The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0-100%), fibrinolysis (18.8%; 0-100%), and no reperfusion therapy (9.0%; 0-75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.55.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8 97.5%) for the performance of reperfusion therapy of all patients with STEMI <12h and 54.4% (region range 37.1-70.1%) for timely reperfusion. Conclusions The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality. [GRAPHICS] .